DR Congo launches Ebola vaccine trials for Bundibugyo strain

Ebola outbreak Bundibugyo virus Ervebo vaccine clinical trials DR Congo

A clinical research program has launched in the Democratic Republic of the Congo to evaluate the effectiveness of the Ervebo vaccine against the Bundibugyo strain of the Ebola virus. The study, known as BRAVO, is being conducted by Médecins Sans Frontières (MSF) and Epicentre in collaboration with the Congolese Ministry of Health, the WHO, and Africa CDC. It aims to immunize approximately 20,000 frontline healthcare workers and responders in the Ituri and North Kivu provinces.

While Ervebo was originally licensed for the Zaire strain of Ebola, preliminary data suggests it may offer a degree of cross-protection against the Bundibugyo variant. The study is expected to last between nine and 12 months. To support the response, 70,000 doses of the vaccine have been made available to Congolese authorities.

The current outbreak has resulted in more than 7,600 confirmed cases and over 3,670 deaths, with nearly 80 percent of infections concentrated in the Ituri province. In response to the crisis, the European Centre for Disease Prevention and Control (ECDC) has deployed two epidemiologists to the region to strengthen surveillance and coordination efforts.

Entities

Bundibugyo virus · Democratic Republic of the Congo · Doctors Without Borders · Epicentre · Ervebo · European Centre for Disease Prevention and Control · Ituri · Médecins Sans Frontières · World Health Organization

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] A total of 70,000 doses of the Ervebo vaccine have been made available to Congolese authorities to support the outbreak response. tanzaniatimes.net · realnewsmagazine.net · healthreporters.info
[● 2 SOURCES] Preliminary data suggests the Ervebo vaccine, originally for Ebola Zaire, may offer some protection against the Bundibugyo virus. www.lapresse.it · prezly.msf.org.uk
[● 3 SOURCES] MSF and Epicentre are launching a study involving up to 20,000 frontline workers in Ituri and North Kivu to evaluate the Ervebo vaccine. www.lapresse.it · prezly.msf.org.uk · www.rnanews.com
[○ 1 SOURCE] Ebola outbreaks represent both a health challenge and a geopolitical issue requiring international cooperation. dazebaonews.it
[● 3 SOURCES] The WHO reports that more than 20,000 doses of the Ervebo vaccine have been allocated for a research program in Ituri, DR Congo. tanzaniatimes.net · realnewsmagazine.net · healthreporters.info
[● 3 SOURCES] The field study launched in Bunia is expected to last between 9 and 12 months. www.lapresse.it · prezly.msf.org.uk · www.rnanews.com
[● 4 SOURCES] Health data indicates over 7,600 confirmed Ebola infections and more than 3,670 deaths. tanzaniatimes.net · realnewsmagazine.net · pt.euronews.com · healthreporters.info
[● 4 SOURCES] Nearly 80 percent of recorded Ebola infections have occurred in the Ituri province. tanzaniatimes.net · realnewsmagazine.net · pt.euronews.com · healthreporters.info
[● 2 SOURCES] The European Centre for Disease Prevention and Control (ECDC) has deployed two epidemiologists to the region to assist with monitoring and response coordination. almakos.com · pt.euronews.com
[● 3 SOURCES] The clinical study is expected to last between nine and 12 months. radio36.com.uy · prezly.msf.org.uk · www.lapresse.it